NASDAQ:ALGS Aligos Therapeutics Q1 2024 Earnings Report $9.37 -0.83 (-8.14%) Closing price 04:00 PM EasternExtended Trading$9.31 -0.06 (-0.63%) As of 05:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Aligos Therapeutics EPS ResultsActual EPS-$5.50Consensus EPS -$4.75Beat/MissMissed by -$0.75One Year Ago EPSN/AAligos Therapeutics Revenue ResultsActual Revenue$0.99 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAligos Therapeutics Announcement DetailsQuarterQ1 2024Date5/7/2024TimeN/AConference Call DateTuesday, May 7, 2024Conference Call Time4:00PM ETUpcoming EarningsAligos Therapeutics' Q3 2025 earnings is scheduled for Wednesday, November 5, 2025, with a conference call scheduled on Thursday, November 6, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Aligos Therapeutics Earnings HeadlinesAligos Therapeutics (NASDAQ:ALGS) Receives Buy Rating from HC WainwrightSeptember 14 at 2:41 AM | americanbankingnews.comAligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV MeetingSeptember 3, 2025 | globenewswire.comWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund. It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you." This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight.September 15 at 2:00 AM | Banyan Hill Publishing (Ad)Aligos Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2, 2025 | globenewswire.comAligos Therapeutics appoints Ramon Polo as head of global regulatory affairsAugust 20, 2025 | msn.comAligos Therapeutics Appoints Ramón Polo as Senior VP, Head of Global Regulatory AffairsAugust 20, 2025 | quiverquant.comQSee More Aligos Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aligos Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aligos Therapeutics and other key companies, straight to your email. Email Address About Aligos TherapeuticsAligos Therapeutics (NASDAQ:ALGS) is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections. Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners. The company’s lead program for chronic hepatitis B (CHB) employs a combination approach to silence viral genes and stimulate immune clearance. In parallel, Aligos is progressing antiviral candidates for respiratory viruses, including coronaviruses and influenza, by targeting key viral enzymes and immune pathways. Aligos’s clinical development strategy emphasizes combination regimens that may offer functional cures rather than life‐long treatment. Its respiratory virus portfolio includes direct‐acting antivirals targeting viral polymerases, alongside immune modulators intended to enhance host defense mechanisms. By integrating novel chemistries with established antiviral targets, the company aims to deliver differentiated therapies across multiple indications. With clinical trials conducted in North America and partnerships extending to global research centers, Aligos is focused on generating robust data to support regulatory filings. The management team brings deep experience in antiviral drug development, clinical operations and regulatory strategy, positioning the company to advance its mission of developing innovative solutions for patients living with chronic and acute viral diseases.View Aligos Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Wall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 EarningsWhy Broadcom's Q3 Earnings Were a Huge Win for AVGO BullsAffirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a Winner Upcoming Earnings FedEx (9/18/2025)Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025)PepsiCo (10/9/2025)BlackRock (10/10/2025)Fastenal (10/13/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
